Barclays PLC cut its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 82.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 169,195 shares of the company’s stock after selling 812,691 shares during the period. Barclays PLC’s holdings in Syndax Pharmaceuticals were worth $3,541,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also modified their holdings of the company. Point72 Hong Kong Ltd bought a new stake in Syndax Pharmaceuticals in the 1st quarter valued at about $41,000. Royal Bank of Canada lifted its position in Syndax Pharmaceuticals by 1,144.7% in the 3rd quarter. Royal Bank of Canada now owns 3,622 shares of the company’s stock valued at $87,000 after purchasing an additional 3,331 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Syndax Pharmaceuticals by 23.1% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,832 shares of the company’s stock valued at $102,000 after purchasing an additional 907 shares during the last quarter. Sandia Investment Management LP bought a new stake in Syndax Pharmaceuticals in the 4th quarter valued at about $127,000. Finally, Exchange Traded Concepts LLC lifted its position in Syndax Pharmaceuticals by 740.7% in the 2nd quarter. Exchange Traded Concepts LLC now owns 7,213 shares of the company’s stock valued at $151,000 after purchasing an additional 6,355 shares during the last quarter.
Syndax Pharmaceuticals Price Performance
NASDAQ SNDX opened at $13.55 on Monday. The company’s 50 day simple moving average is $14.50 and its 200 day simple moving average is $18.33. Syndax Pharmaceuticals, Inc. has a 12 month low of $11.22 and a 12 month high of $29.86. The company has a market capitalization of $943.64 million, a P/E ratio of -5.25 and a beta of 1.04.
Wall Street Analyst Weigh In
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).
- Five stocks we like better than Syndax Pharmaceuticals
- Dividend Payout Ratio Calculator
- MarketBeat Week in Review – 11/6 – 11/10
- Canada Bond Market Holiday: How to Invest and Trade
- Data giants MongoDB and Snowflake just got upgraded
- Which Wall Street Analysts are the Most Accurate?
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.